Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1118520230200121195
Psychiatry Investigation
2023 Volume.20 No. 12 p.1195 ~ p.1203
A Case-Control Clinical Trial on a Deep Learning-Based Classification System for Diagnosis of Amyloid-Positive Alzheimer¡¯s Disease
Bae Jong-Bin

Lee Su-Bin
Oh Hyun-Woo
Sung Jin-Kyeong
Lee Dong-Soo
Han Ji-Won
Kim Jun-Sung
Kim Jae-Hyoung
Kim Sang-Eun
Kim Ki-Woong
Abstract
Objective: A deep learning-based classification system (DLCS) which uses structural brain magnetic resonance imaging (MRI) to diagnose Alzheimer¡¯s disease (AD) was developed in a previous recent study. Here, we evaluate its performance by conducting a single-center, case-control clinical trial.

Methods: We retrospectively collected T1-weighted brain MRI scans of subjects who had an accompanying measure of amyloid-beta (A¥â) positivity based on a 18F-florbetaben positron emission tomography scan. The dataset included 188 A¥â-positive patients with mild cognitive impairment or dementia due to AD, and 162 A¥â-negative controls with normal cognition. We calculated the sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUC) of the DLCS in the classification of A¥â-positive AD patients from A¥â-negative controls.

Results: The DLCS showed excellent performance, with sensitivity, specificity, positive predictive value, negative predictive value, and AUC of 85.6% (95% confidence interval [CI], 79.8?90.0), 90.1% (95% CI, 84.5?94.2), 91.0% (95% CI, 86.3?94.1), 84.4% (95% CI, 79.2?88.5), and 0.937 (95% CI, 0.911?0.963), respectively.

Conclusion: The DLCS shows promise in clinical settings where it could be routinely applied to MRI scans regardless of original scan purpose to improve the early detection of AD.
KEYWORD
Alzheimer disease, Magnetic resonance imaging, Clinical trial, Deep learning
FullTexts / Linksout information
 
Listed journal information